This site is intended for health professionals only
Friday 24 May 2019
Share |

Alteplase safe for acute stroke

Stroke registry confirms the safety of alteplase thrombolysis treatment

Results from SITS-MOST (Safe Implementation of Thrombolysis in Stroke – Monitoring Study) have confirmed that routine clinical thrombolysis therapy with alteplase (Actilyse), the first and only approved treatment for acute ischaemic stroke, is as safe and effective as previously reported in randomised controlled trials when administered within three hours of onset of a stroke.

The SITS-MOST results show that mortality rates following alteplase treatment were even better in routine practice than had previously been seen in randomised controlled trials (11.3% vs 17.3%). Furthermore, the incidence of symptomatic haemorrhages and of functional independence at three months were comparable to those observed in randomised controlled trials.

SITS-MOST is an open, prospective, observational safety monitoring study for centres practising thrombolysis for acute stroke in Europe. It is the largest stroke registry worldwide, with 6,483 patients recruited to the trial in 285 centres across 14 European countries.


Ads by Google

You are leaving

You are currently leaving the Nursing in Practice site. Are you sure you want to proceed?


Respect for nurses: Sign up to our e-petition TODAY

The Nursing in Practice Respect campaign is now live! Over the coming months, we're set to highlight the vital contribution and efforts of primary care and community care nurses throughout the UK.

As part of our campaign, Nursing in Practice is looking to call on parliament to set up a debate to celebrate the vital work that you do.



Calling all primary care nurses! 'Like' our Nursing in Practice Facebook page to enter our free draw to win a £25 M&S voucher